Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone
- Autores
- Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; Latella, Antonio; Zubizarreta, Pedro
- Año de publicación
- 2014
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.
Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pollono, Daniel. No especifica;
Fil: Rey, Guadalupe. No especifica;
Fil: Lagomarsino, Eduardo. No especifica;
Fil: Latella, Antonio. No especifica;
Fil: Zubizarreta, Pedro. No especifica; - Materia
-
Histiocytosis
Indomethacin Therapy
Pediatric
Bone Langerhans Cell Histiocytosis
Outcome - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/29381
Ver los metadatos del registro completo
id |
CONICETDig_ef0edf0b04710a31c40781b96a36369c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/29381 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin aloneBraier, JorgeRosso, DiegoPollono, DanielRey, GuadalupeLagomarsino, EduardoLatella, AntonioZubizarreta, PedroHistiocytosisIndomethacin TherapyPediatricBone Langerhans Cell HistiocytosisOutcomehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease.Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pollono, Daniel. No especifica;Fil: Rey, Guadalupe. No especifica;Fil: Lagomarsino, Eduardo. No especifica;Fil: Latella, Antonio. No especifica;Fil: Zubizarreta, Pedro. No especifica;Lippincott Williams2014-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/29381Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e2841077-4114enginfo:eu-repo/semantics/altIdentifier/doi/10.1097/MPH.0000000000000165001info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jpho-online/pages/articleviewer.aspx?year=2014&issue=07000&article=00022&type=abstractinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:08:31Zoai:ri.conicet.gov.ar:11336/29381instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:08:32.246CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
title |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
spellingShingle |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone Braier, Jorge Histiocytosis Indomethacin Therapy Pediatric Bone Langerhans Cell Histiocytosis Outcome |
title_short |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
title_full |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
title_fullStr |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
title_full_unstemmed |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
title_sort |
Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone |
dc.creator.none.fl_str_mv |
Braier, Jorge Rosso, Diego Pollono, Daniel Rey, Guadalupe Lagomarsino, Eduardo Latella, Antonio Zubizarreta, Pedro |
author |
Braier, Jorge |
author_facet |
Braier, Jorge Rosso, Diego Pollono, Daniel Rey, Guadalupe Lagomarsino, Eduardo Latella, Antonio Zubizarreta, Pedro |
author_role |
author |
author2 |
Rosso, Diego Pollono, Daniel Rey, Guadalupe Lagomarsino, Eduardo Latella, Antonio Zubizarreta, Pedro |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
Histiocytosis Indomethacin Therapy Pediatric Bone Langerhans Cell Histiocytosis Outcome |
topic |
Histiocytosis Indomethacin Therapy Pediatric Bone Langerhans Cell Histiocytosis Outcome |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease. Fil: Braier, Jorge. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina Fil: Rosso, Diego. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Pollono, Daniel. No especifica; Fil: Rey, Guadalupe. No especifica; Fil: Lagomarsino, Eduardo. No especifica; Fil: Latella, Antonio. No especifica; Fil: Zubizarreta, Pedro. No especifica; |
description |
This study evaluated the outcome of patients with symptomatic bone Langerhans cell histiocytosis (LCH) treated with indomethacin alone, either at diagnosis or after reactivation (after recurrence with previous therapies). We evaluated the nonrandomized use of oral indomethacin (2 mg/kg/d) in patients with symptomatic single-system bone LCH. From 1997 to 2012, 38 sequential patients were treated for a median of 4 months. Criteria of nonactive disease (NAD) after initial treatment (8 wk) were: no pain, no soft tissue involvement, no increase of size, or no new bone lesions. Twentytwo patients were treated at diagnosis: 18 showed NAD after initial treatment (2 patients who had bone reactivations were retreated with indomethacin and remain with NAD). Three patients improved and they are with NAD after treatment with indomethacin, steroids, or radiotherapy. One patient developed progressive bone disease and he is with NAD after treatment with steroids and chemotherapy. Sixteen patients were treated after reactivation, and all were with NAD after initial treatment: 5 reactivated and 4 remain with NAD after retreatment with indomethacin. Toxicity was not significant. We conclude that indomethacin is a well tolerated and active drug in patients with symptomatic bone disease. The results support the concept that chemotherapy may not be necessary for limited bone disease. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-07 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/29381 Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e284 1077-4114 |
url |
http://hdl.handle.net/11336/29381 |
identifier_str_mv |
Braier, Jorge; Rosso, Diego; Pollono, Daniel; Rey, Guadalupe; Lagomarsino, Eduardo; et al.; Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone; Lippincott Williams; Journal Of Pediatric Hematology Oncology; 36; 5; 7-2014; e280-e284 1077-4114 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1097/MPH.0000000000000165001 info:eu-repo/semantics/altIdentifier/url/http://journals.lww.com/jpho-online/pages/articleviewer.aspx?year=2014&issue=07000&article=00022&type=abstract |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Lippincott Williams |
publisher.none.fl_str_mv |
Lippincott Williams |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842270048941506560 |
score |
13.13397 |